Journal Article
. 2017 Jul; 18(9):1211-1220.
doi: 10.1016/S1470-2045(17)30419-9.

Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial

Marloes G M Derks 1 Erik J Blok 2 Caroline Seynaeve 3 Johan W R Nortier 4 Elma Meershoek-Klein Kranenbarg 1 Gerrit-Jan Liefers 1 Hein Putter 5 Judith R Kroep 4 Daniel Rea 6 Annette Hasenburg 7 Christos Markopoulos 8 Robert Paridaens 9 Jan B E Smeets 10 Luc Y Dirix 11 Cornelis J H van de Velde 12 
Affiliations
  • PMID: 28732650
  •     15 citations

Abstract

Background: After 5 years of median follow-up, the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial reported no difference in disease-free survival between exemestane monotherapy and a sequential scheme of tamoxifen followed by exemestane in postmenopausal patients with early-stage, hormone receptor-positive breast cancer. As recurrence risk in hormone receptor-positive breast cancer remains linear beyond 5 years after diagnosis, we analysed long-term follow-up outcomes of this trial.

Methods: The TEAM trial, a multicentre, open-label, randomised, controlled, phase 3 trial, included postmenopausal patients with early-stage hormone receptor-positive breast cancer from nine countries. Patients were randomly allocated (1:1) by a computer-generated random permuted block method (block sizes 4-8) to either 5 years of oral exemestane monotherapy (25 mg once a day) or a sequential scheme of oral tamoxifen (20 mg once a day) followed by exemestane for a total duration of 5 years. After the publication of the IES trial, the protocol was amended (Dec 13, 2004). Patients assigned to tamoxifen were switched after 2·5-3·0 years to exemestane therapy for a total duration of 5·0 years of treatment. Randomisation was done centrally in each country. Long-term follow-up data for disease recurrence and survival was collected in six participating countries and analysed by intention to treat. The primary endpoint was disease-free survival at 10 years of follow-up. The trial is registered with ClinicalTrials.gov, numbers NCT00279448 and NCT00032136; with Netherlands Trial Register, number NTR 267; and the Ethics Commission Trial, number 27/2001.

Findings: 6120 patients of the original 9776 patients in the TEAM trial were included in the current intention-to-treat analysis. Median follow-up was 9·8 years (IQR 8·0-10·3). During follow-up, 921 (30%) of 3075 patients in the exemestane group and 929 (31%) of 3045 patients in the sequential group had a disease-free survival event. Disease-free survival at 10 years was 67% (95% CI 65-69) for the exemestane group and 67% (65-69) for the sequential group (hazard ratio 0·96, 0·88-1·05; p=0·39).

Interpretation: The long-term findings of the TEAM trial confirm that both exemestane alone and sequential treatment with tamoxifen followed by exemestane are reasonable options as adjuvant endocrine therapy in postmenopausal patients with hormone receptor-positive early breast cancer. These results suggest that the opportunity to individualise adjuvant endocrine strategy accordingly, based on patient preferences, comorbidities, and tolerability might be possible.

Funding: Pfizer, Dutch Cancer Foundation.

Breast cancer: 10-year follow-up of the TEAM cohort reported.
Peter Sidaway.
Nat Rev Clin Oncol, 2017 Aug 16; 14(10). PMID: 28812598
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
Erik J Blok, Judith R Kroep, +8 authors, IDEAL Study Group.
Breast Cancer Res Treat, 2017 Dec 13; 168(2). PMID: 29230665    Free PMC article.
Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
F Khosrow-Khavar, H Yin, +2 authors, L Azoulay.
Ann Oncol, 2018 Jan 03; 29(3). PMID: 29293897    Free PMC article.
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
Irene E G van Hellemond, Sandra M E Geurts, Vivianne C G Tjan-Heijnen.
Curr Treat Options Oncol, 2018 Apr 29; 19(5). PMID: 29704066    Free PMC article.
Review.
Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells.
Boya Deng, Yunus Emre Tarhan, +4 authors, Yusuke Nakamura.
Neoplasia, 2018 Sep 13; 20(10). PMID: 30208353    Free PMC article.
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Thomas Ruhstaller, Anita Giobbie-Hurder, +27 authors, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group.
J Clin Oncol, 2018 Nov 27; 37(2). PMID: 30475668    Free PMC article.
Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer.
Marloes G M Derks, Cornelis J H van de Velde, +7 authors, Gerrit-Jan Liefers.
Oncologist, 2019 Jan 05; 24(7). PMID: 30606886    Free PMC article.
Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.
Clara Inkyung Lee, Siew Kee Low, +14 authors, Howard Gurney.
Breast, 2020 Nov 09; 54. PMID: 33161337    Free PMC article.
SEOM clinical guidelines in early stage breast cancer (2018).
F Ayala de la Peña, R Andrés, +7 authors, E Ciruelos.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30443868    Free PMC article.
New small-molecule compound Hu-17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells.
Yang Xi, Jiansheng Liu, +3 authors, Yanzhi Du.
Cancer Med, 2020 Oct 02; 9(23). PMID: 33002342    Free PMC article.
Precautions for Patients Taking Aromatase Inhibitors.
Mary Heery, Stephen Farley, +4 authors, Richard Zelkowitz.
J Adv Pract Oncol, 2021 Feb 04; 11(2). PMID: 33532117    Free PMC article.
The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.
Danny Houtsma, Stefanie de Groot, +7 authors, Hans Gelderblom.
Sci Rep, 2021 Feb 07; 11(1). PMID: 33547330    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis.
Nina Tamirisa, Heather Lin, +5 authors, Isabelle Bedrosian.
Cancer, 2021 Mar 19; 127(13). PMID: 33735487    Free PMC article.
Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study.
Ariane Mamguem Kamga, Oumar Billa, +7 authors, Tienhan Sandrine Dabakuyo-Yonli.
Breast, 2021 Jun 27; 59. PMID: 34174766    Free PMC article.